Carpenter Technology Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Tony R. Thene
- Full Time Employees
- 4,600
- Sector
- Industrials
- Industry
- Manufacturing - Metal Fabrication
- Address
- 1735 Market Street Philadelphia PA United States of America 19103
- IPO Date
- Nov 5, 1987
- CIK
- 0000017843
- Website
- carpentertechnology.com
- Similar Companies
- Business
- Carpenter Technology Corporation (NYSE: CRS) manufactures and distributes premium specialty alloys, stainless steels, nickel, cobalt, titanium, and superalloys, as well as metal powders for additive manufacturing and precision engineered components; its core offerings encompass high-temperature superalloys, high-strength steels, implantable and biocompatible alloys, controlled expansion alloys, tool and die steels, titanium products including wire, bar, strip and shaped components, gas-atomized pre-alloyed powders, and custom parts with value-added services such as contract manufacturing and alloy conversion. The company operates through two primary segments: Specialty Alloys Operations, which produces premium alloys and stainless steels at facilities in the United States, Europe, and Asia; and Performance Engineered Products, which includes titanium manufacturing via Dynamet Incorporated, additive manufacturing through Carpenter Additive, powder production, and distribution services across the U.S., Canada, Mexico, North America, and South America. These products serve critical applications in aerospace and defense (including engines, landing gear, and precision components), medical (prosthetics, surgical instruments, and orthopedics), transportation, energy (power generation, oil and gas), industrial, consumer goods, and electrification markets. Founded in 1889 and headquartered in Philadelphia, Pennsylvania, with key manufacturing sites in Reading, Pennsylvania; Tanner, Alabama; and Hartsville, South Carolina, the company targets high-performance needs in mission-critical sectors globally. In recent developments, Carpenter Technology closed a $700.0 million private offering of 5.625% senior notes due 2034 in November 2025 and amended its credit agreement to expand revolving commitments from $350 million secured to $500 million unsecured, extending maturity to 2030 with an accordion feature up to $650 million. The company continues a major brownfield expansion project at its Athens, Alabama facility to increase primary and secondary melt capacity, with construction underway, on schedule and budget, and capital spending accelerating in fiscal 2026 to support aerospace demand growth. Strong fiscal 2025 and first quarter 2026 results reflect record operating income, robust aerospace and defense revenue exceeding 60% of total (up sequentially and year-over-year), share repurchases totaling over $150 million under a $400 million authorization, and optimistic guidance for $660-$700 million operating income in fiscal 2026 and $765-$800 million in 2027 driven by multi-year demand in key markets.
Will Carpenter (CRS) Beat Estimates Again in Its Next Earnings Report?
Carpenter Technology Announces Conference Call and Webcast
3 Reasons Why Growth Investors Shouldn't Overlook Carpenter (CRS)
Are You Looking for a Top Momentum Pick? Why Carpenter Technology (CRS) is a Great Choice
DelphX Capital Markets Provides Corporate Update on Structured Income Program and CRS Commercialization
Carpenter Technology (CRS) is a Top-Ranked Momentum Stock: Should You Buy?
Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish
Supporting the Mission: Catholic Relief Services Chooses Adstra as a Fundraising Partner
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
Why X Money Could Be Bigger Than PayPal Ever Was
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
Carpenter Technology Corporation (CRS) Hits Fresh High: Is There Still Room to Run?
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Term
Carpenter Technology (CRS) Is Up 8.03% in One Week: What You Should Know
Carpenter (CRS) Upgraded to Buy: Here's Why
ARKX vs. XAR: Two ETFs Worthy of Consideration
Carpenter Technology Gains on Record Earnings, Profits
Which Is the Better Aerospace and Defense ETF, Invesco's PPA or State Street's XAR?